


SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549



02041659

FORM 6-K



REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934

*P.E.*  
June 20, 2002

Provalis plc  
(Translation of Registrant's Name into English)

Newtech Square  
Deeside Industrial Park  
Deeside  
Flintshire  
CH5 2NT  
(Address of Principle Executive Offices)

PROCESSED  
JUN 27 2002  
THOMSON  
FINANCIAL

(Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.)

Form 20-F  Form 40-F

(Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.)

Yes  No

(If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_.)

RECEIVED TIME JUN. 20. 12:54PM

PRINT TIME JUN. 20. 12:56PM

For Immediate Release

20 June 2002

### **Provalis Distribution Agreement for Pennsaid**

Provalis (LSE: PRO; NASDAQ: PVLS) has now reviewed its position with regard to the unexpected notice from Dimethaid purporting to terminate the Agreement under which Provalis distributes Pennsaid in the UK, details of which were announced by Provalis on 14<sup>th</sup> June 2002.

Provalis has concluded that, whilst Dimethaid was not entitled to terminate the Agreement, the actions taken by Dimethaid have irreparably damaged the relationship between the two companies. As a consequence, Provalis has no alternative but to treat the Agreement as terminated and is now looking to Dimethaid for full compensation for its losses. Notice of this has been given to Dimethaid today.

Provalis will consider at the year end the carrying value of the investment made in Pennsaid.

END

**Provalis' Internet Website ; <http://www.provalis.com>**

**"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995:** Statements in this announcement that relate to future plans, expectations, events, performances and the like are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors. Such factors include, among others: the success of the Group's research and development strategy; uncertainties related to future trial results and the regulatory process; the execution and success of collaborative agreements with third parties; the impact of future laws, regulations and policies; the Group's intellectual property position and the success of patent applications for its products and technologies; stock market trends in the Group's sector; the Group's dependence on key personnel; general business and economic conditions; and other factors beyond the Group's control that may cause the Group's available capital resources to be used more quickly than expected. These and other factors that could affect the Company's future results are more fully described in its filings with the US Securities and Exchange Commission, in particular the latest 20-F filing, copies of which are available from the Company Secretary at the Company's registered address.

---

**For further information:-**

Dr Phil Gould, Provalis plc,  
Mr Lee Greenbury, Provalis plc,  
Lisa Baderoon, Buchanan Communications,

Tel: 01244 833463  
Tel: 01244 833402  
Tel: 020 7466 5000

**Notes to Editors**

**Provalis plc** (LSE.PRO and NASDAQ.PVLS) is a healthcare company with three separate divisions:-


- **Medical Diagnostics** – develops and sells to world markets medical diagnostic products for chronic disease management. The division's principle products are Glycosal® and Osteosal® in the areas of diabetes and osteoporosis respectively.
- **Healthcare** – sells and markets its own, and third party, branded, prescription medicines in the UK to GPs and hospitals through its own regionally managed sales force. The division sells products in the areas of muscular-skeletal disorders, gastroenterology, osteoporosis, migraine and dermatology.
- **Therapeutics R&D** – develops a range of vaccine candidates for the prevention of infectious diseases through a network of research collaborators.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Provalis plc

Date: June 20, 2002

By: 

Name: Lee Greenbury

Title: Secretary